The immune mechanisms in stroke involve innate immunity and adaptive immunity. A variety of immune cells are involved in causing ischemic brain damage, such as microglia, neutrophils, natural killer (NK) cells, T lymphocytes, B lymphocytes, monocytes, and dendritic cells (DCs). Immune cells may also trigger or promote cytotoxic edema and neuronal death through the compromised blood-brain barrier (BBB) in cerebral hemorrhage. Since stroke induces a rapid and massive immune response, immune cells and inflammatory mediators have emerged as promising therapeutic targets for ischemic and hemorrhagic stroke.
Fig. 1. Neutrophils activation and adhesion in acute ischemic stroke. (Jickling, et al., 2015)
What We Offer
Ace Therapeutics provides reliable services for the development of stroke drugs that target immune cells. With a team of experts in immunology, neuroscience, pharmacology and medicinal chemistry, advanced equipment and proprietary methodologies, we can provide you with a one-stop stroke drug discovery service and accelerate your drug development process. Our services can be tailored to meet the specific needs of our clients' drug development programs.
Microglia undergo multiple phenotypic changes under ischemic stroke conditions, and the different stages of microglial phenotypic shifts contribute to their complexity. We can help clients develop novel therapeutic strategies to convert microglia to a protective phenotype by targeting the following targets.
Prostaglandin E2 (PGE2) | Toll-like receptor 4 (TLR4) | Sphingosine-1-phosphate (S1P) |
NLRP3 | Nuclear factor-κB (NF-κB) | STAT family members |
We can help clients analyze the role of neutrophils in ischemic stroke and preclinically develop one or more therapeutic strategies targeting neutrophils as a treatment for ischemic stroke, including:
ICAM-1 | CD11b | CD18 | E selectin |
L selectin | CXCR1 | CXCR2 | CCR2 |
P38 MAPK | HMGB1-TLR4 | Robo1 | Slit1 |
Protein kinase C | CD47 | CD73 | TLR4 |
Ace Therapeutics provides comprehensive immune cell screening, drug design and preclinical evaluation services to help pharmaceutical companies accelerate the translation of innovative immunotherapies for stroke from the laboratory to the clinic. If you are interested in our services, please do not hesitate to contact us!
We are committed to accelerating progress in stroke research and drug development.